Research ArticleAccepted Article
Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs
Neil McHugh, Áine Maguire, Ian Handel, William Tillett, James Morris, Neil Hawkins, Charlotte Cavill, Eleanor Korendowych and Farhan Mughal
The Journal of Rheumatology August 2019, jrheum.190083; DOI: https://doi.org/10.3899/jrheum.190083
Neil McHugh
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
Áine Maguire
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
Ian Handel
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
William Tillett
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
James Morris
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
Neil Hawkins
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
Charlotte Cavill
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
Eleanor Korendowych
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
Farhan Mughal
From the Royal National Hospital for Rheumatic Disease, NHS Foundation Trust, Bath, UK; University of Cambridge, Cambridge, UK; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK; University of Bath, Bath, UK; Cogentia Healthcare Consulting Ltd, Cambridge, UK; University of Glasgow, Glasgow, UK; and Celgene Ltd, Uxbridge, UK. Supported by Celgene Ltd. Conflicts of interest: N. McHugh has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Pfizer and UCB. Á. Maguire has received grant/research support from Cogentia Healthcare Consulting Ltd. I. Handel has received personal fees for statistical analyses from Visible Analytics Limited. W. Tillett has received speaker/consultancy fees and/or grants from AbbVie, Celgene Ltd, Eli Lilly, Janssen, Novartis, Pfizer and UCB. J. Morris has received consultancy fees from Celgene Ltd. N. Hawkins has received grant/research support from Celgene Ltd. C. Cavill has received grant/research support from Celgene Ltd. E. Korendowych has received grant/research support from AbbVie, Celgene Ltd and Pfizer, and consultancy/speaker fees from AbbVie, Celgene Ltd, Janssen, Novartis and Pfizer. F. Mughal was an employee of Celgene Ltd at the time of study conduct. Address correspondence to: Prof. Neil McHugh, Department of Pharmacy and Pharmacology, University of Bath Claverton Down, Bath BA27AY, UK. Telephone +44 (0)1225 284228. Email: n.j.mchugh@bath.ac.uk.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs
Neil McHugh, Áine Maguire, Ian Handel, William Tillett, James Morris, Neil Hawkins, Charlotte Cavill, Eleanor Korendowych, Farhan Mughal
The Journal of Rheumatology Aug 2019, jrheum.190083; DOI: 10.3899/jrheum.190083
Accepted manuscript
Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs
Neil McHugh, Áine Maguire, Ian Handel, William Tillett, James Morris, Neil Hawkins, Charlotte Cavill, Eleanor Korendowych, Farhan Mughal
The Journal of Rheumatology Aug 2019, jrheum.190083; DOI: 10.3899/jrheum.190083